Analysts predict that Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) will report $7.32 million in sales for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Arrowhead Pharmaceuticals’ earnings, with the highest sales estimate coming in at $8.00 million and the lowest estimate coming in at $6.63 million. Arrowhead Pharmaceuticals posted sales of $30,000.00 during the same quarter last year, which would indicate a positive year over year growth rate of 24,300%. The business is expected to issue its next quarterly earnings results on Wednesday, December 13th.

According to Zacks, analysts expect that Arrowhead Pharmaceuticals will report full year sales of $7.32 million for the current year, with estimates ranging from $29.32 million to $35.00 million. For the next fiscal year, analysts anticipate that the business will post sales of $11.75 million per share, with estimates ranging from $8.50 million to $15.00 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that follow Arrowhead Pharmaceuticals.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.07) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.13) by $0.06. Arrowhead Pharmaceuticals had a negative return on equity of 46.73% and a negative net margin of 201.84%. The firm had revenue of $9.34 million for the quarter, compared to the consensus estimate of $5.29 million.

A number of research analysts have recently issued reports on ARWR shares. Jefferies Group LLC reiterated a “hold” rating and issued a $2.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Friday, August 4th. Piper Jaffray Companies reiterated a “hold” rating and issued a $2.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Friday, July 28th. Finally, ValuEngine upgraded shares of Arrowhead Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Thursday. One equities research analyst has rated the stock with a sell rating and five have issued a hold rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $1.80.

Hedge funds and other institutional investors have recently bought and sold shares of the company. LMR Partners LLP bought a new position in Arrowhead Pharmaceuticals during the second quarter valued at $467,000. Wells Fargo & Company MN boosted its position in Arrowhead Pharmaceuticals by 144.8% in the first quarter. Wells Fargo & Company MN now owns 150,346 shares of the biotechnology company’s stock valued at $278,000 after buying an additional 88,933 shares during the period. SG Americas Securities LLC boosted its position in Arrowhead Pharmaceuticals by 287.9% in the first quarter. SG Americas Securities LLC now owns 100,747 shares of the biotechnology company’s stock valued at $186,000 after buying an additional 74,776 shares during the period. UBS Asset Management Americas Inc. boosted its position in Arrowhead Pharmaceuticals by 414.7% in the first quarter. UBS Asset Management Americas Inc. now owns 66,400 shares of the biotechnology company’s stock valued at $123,000 after buying an additional 53,500 shares during the period. Finally, Virtu KCG Holdings LLC boosted its position in Arrowhead Pharmaceuticals by 115.6% in the second quarter. Virtu KCG Holdings LLC now owns 99,267 shares of the biotechnology company’s stock valued at $161,000 after buying an additional 53,215 shares during the period. Hedge funds and other institutional investors own 29.89% of the company’s stock.

Shares of Arrowhead Pharmaceuticals (NASDAQ ARWR) opened at 2.58 on Friday. The stock’s market capitalization is $192.91 million. Arrowhead Pharmaceuticals has a 1-year low of $1.20 and a 1-year high of $8.09. The company has a 50 day moving average price of $1.82 and a 200-day moving average price of $1.79.

WARNING: “$7.32 Million in Sales Expected for Arrowhead Pharmaceuticals, Inc. (ARWR) This Quarter” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another domain, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this article can be read at https://www.thecerbatgem.com/2017/08/27/7-32-million-in-sales-expected-for-arrowhead-pharmaceuticals-inc-arwr-this-quarter.html.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.

Get a free copy of the Zacks research report on Arrowhead Pharmaceuticals (ARWR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Stock Ratings for Arrowhead Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.